Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies
Could Be Worth $900m
News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.
News of the deal emerged as the UK firm's shares skyrocketed after its SPEAR T-cell platform delivered responses in four solid tumor types.